UK-based Storm Therapeutics Ltd, which is developing small molecules that target RNA-modifying enzymes in cancer, has raised £12 million in Series A equity financing. Two heavy-weight corporate venture capitalists participated in the financing, suggesting interest in the technology.
London, UK-based Tiziana Life Sciences Plc has expanded into genomic medicine with the purchase of a large biobank from Shardna SpA of Italy that has information on 13,000 genealogically linked residents of the Ogliastra region of Sardinia.
Bayer AG, whose name is usually associated with aspirin, has signaled its intention to deepen its commitment to crop science by raising its takeover bid for Monsanto Inc to $125 per share. The move values the company at $64 billion.
Cell Medica Ltd has completed another stage of its strategy for developing immunotherapies for solid tumours with the acquisition of Delenex Therapeutics AG, an antibody specialist based in Switzer
GW Pharmaceuticals Plc has raised gross proceeds of $252 million on the US Nasdaq market with the issue of 2.8 million American Depositary Shares (ADSs) to investors at a price of $90 per ADS.
The US biotech, Medivation Inc, has been successful at buying in new medicines for further development, but will selling itself be its most successful deal?
A new UK medical device company with technology that aims to improve current methods of ablating tissue in tumours has been launched with seed funding of £500,000. Ablatus Therapeutics Ltd is a spin out of the Norfolk & Norwich University Hospitals NHS Foundation Trust.
Nicox SA is undertaking another strategic reorganisation with plans to spin out its portfolio of marketed ophthalmology products in Europe into a new company in which it will have a minority stake. It will keep a R&D portfolio that includes two products in registration in the US.
Milan, Italy-based Dianax has received a €2 million European Union grant to support development of a portable diagnostic for the prevention and monitoring of diabetes. The device is designed to provide measurements of glycated haemoglobin.
Evotec AG, whose extensive drug discovery business is divided between services for biotech companies and proprietary work, has obtained non-exclusive access to the gene-editing tool CRISPR/Cas9 in order to strengthen its screening and target identification activities.